Nascent Biotech

Nascent Biotech is building a portfolio of innovative therapeutic antibodies.

The innate ability of the intelligence of the natural human immune system to generate a cancer specific response combined with NBI’s technical skills opens the door for immunologically based therapeutics for human cancer. NBI is using and developing human antibodies and cytokine responses obtained from the innate natural human immune response as a drug discovery platform for identifying new antibodies and antigens for commercialization. Our insight into the natural human immune response defines important targets for therapeutic intervention thus enabling the rapid development of new classes of safe, non-toxic, and specific biological drugs for use in the clinic.